GT Biopharma, Inc.
GTBPNASDAQHealthcare● Active
$0.43
$-0.01(-2.57%)
Market Cap$4516410
P/E Ratio—
52W High$3.85
52W Low$0.261
GT Biopharma, Inc. (GTBP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GTBP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.11
Est. -$0.08 · -37.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS
GTBP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.08 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.08 | -$0.11 | -37.5% | — | — | — |
| ▼ Q1 FY2026 | Mar 2, 2026 | -$0.22 | -$2.22 | -909.1% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.38 | -$0.83 | -118.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.68 | -$0.55 | +19.1% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.64 | -$0.76 | -18.8% | — | — | — |
| ▼ Q1 FY2025 | Feb 21, 2025 | -$1.55 | -$1.66 | -7.1% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$2.70 | -$1.53 | +43.3% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.11
EPS Est.
-$0.08
EPS Surpr.
-37.5%
Revenue
—
Q1 FY2026
Mar 2, 2026Miss
EPS Actual
-$2.22
EPS Est.
-$0.22
EPS Surpr.
-909.1%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.83
EPS Est.
-$0.38
EPS Surpr.
-118.4%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.55
EPS Est.
-$0.68
EPS Surpr.
+19.1%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.76
EPS Est.
-$0.64
EPS Surpr.
-18.8%
Revenue
—
Q1 FY2025
Feb 21, 2025Miss
EPS Actual
-$1.66
EPS Est.
-$1.55
EPS Surpr.
-7.1%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$1.53
EPS Est.
-$2.70
EPS Surpr.
+43.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q2 FY2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q1 FY2026 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q4 FY2025 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q3 FY2025 | $-0.38 | $-0.38 | $-0.38 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -37.5% | $0.44 | $0.39 | -10.25% |
| ▼ Q1 FY2026 | Mar 2, 2026 | -909.1% | $0.48 | $0.47 | -2.30% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -118.4% | $0.73 | $0.92 | +26.14% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +19.1% | $1.68 | $1.45 | -13.69% |
| ▼ Q2 FY2025 | May 15, 2025 | -18.8% | $2.19 | $2.24 | +2.28% |
| ▼ Q1 FY2025 | Feb 21, 2025 | -7.1% | $2.13 | $2.15 | +0.94% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +43.3% | $3.06 | $3.01 | -1.63% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +17.0% | $2.41 | $2.29 | -4.98% |
Q2 FY2026-10.25%
Report Date
May 15, 2026
EPS Beat/Miss
-37.5%
Price Before
$0.44
Price After
$0.39
Q1 FY2026-2.30%
Report Date
Mar 2, 2026
EPS Beat/Miss
-909.1%
Price Before
$0.48
Price After
$0.47
Q4 FY2025+26.14%
Report Date
Nov 14, 2025
EPS Beat/Miss
-118.4%
Price Before
$0.73
Price After
$0.92
Q3 FY2025-13.69%
Report Date
Aug 14, 2025
EPS Beat/Miss
+19.1%
Price Before
$1.68
Price After
$1.45
Q2 FY2025+2.28%
Report Date
May 15, 2025
EPS Beat/Miss
-18.8%
Price Before
$2.19
Price After
$2.24
Q1 FY2025+0.94%
Report Date
Feb 21, 2025
EPS Beat/Miss
-7.1%
Price Before
$2.13
Price After
$2.15
Q4 FY2024-1.63%
Report Date
Nov 14, 2024
EPS Beat/Miss
+43.3%
Price Before
$3.06
Price After
$3.01
Q3 FY2024-4.98%
Report Date
Aug 14, 2024
EPS Beat/Miss
+17.0%
Price Before
$2.41
Price After
$2.29
Avg Beat Reaction-6.77%
Avg Miss Reaction+3.36%
Beat Rate3 / 8 quarters
Largest Move+26.14% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GTBP ends December
GT Biopharma, Inc. (GTBP) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.11 — missing the analyst consensus of $-0.08 by -37.5%. The next GTBP earnings date is expected around September 1, 2026.
Each quarter, investors track GTBP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GTBP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GTBP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GTBP earnings · 5 questionsGT Biopharma, Inc.'s next earnings report is expected around September 1, 2026. GTBP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GTBP historically reports after market close (AMC).
GTBP earnings datewhen is GTBP earningsGTBP next earnings datewhen does GTBP report earningsGTBP earnings calendar
▸ Source: FMP · GT Biopharma, Inc. SEC filings · US GAAP · GT Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026